Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
2.

Trehalose improves human fibroblast deficits in a new CHIP-mutation related ataxia.

Casarejos MJ, Perucho J, López-Sendón JL, García de Yébenes J, Bettencourt C, Gómez A, Ruiz C, Heutink P, Rizzu P, Mena MA.

PLoS One. 2014 Sep 26;9(9):e106931. doi: 10.1371/journal.pone.0106931. eCollection 2014.

3.

WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.

Downing NR, Kim JI, Williams JK, Long JD, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Eur J Hum Genet. 2014 Aug;22(8):958-63. doi: 10.1038/ejhg.2013.275. Epub 2013 Dec 11.

4.

A 5-year follow-up of deep brain stimulation in Huntington's disease.

López-Sendón Moreno JL, García-Caldentey J, Regidor I, del Álamo M, García de Yébenes J.

Parkinsonism Relat Disord. 2014 Feb;20(2):260-1. doi: 10.1016/j.parkreldis.2013.11.007. Epub 2013 Nov 16. No abstract available.

PMID:
24300048
5.

The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease.

Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S; PSP Genetics Study Group, Lee VM, Trojanowski JQ, Devlin B, Schellenberg GD.

Acta Neuropathol Commun. 2013 Jul 6;1:31. doi: 10.1186/2051-5960-1-31.

6.

Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.

Moreno JL, Palau Fayos JM, Díaz de Santiago A, García de Yébenes J.

J Huntingtons Dis. 2012;1(1):31-2. doi: 10.3233/JHD-2012-120008. No abstract available.

PMID:
25063189
7.

Discrepancies in reporting the CAG repeat lengths for Huntington's disease.

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.

Eur J Hum Genet. 2012 Jan;20(1):20-6. doi: 10.1038/ejhg.2011.136. Epub 2011 Aug 3.

8.

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD.

Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

9.

Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease.

Carlozzi NE, Stout JC, Mills JA, Duff K, Beglinger LJ, Aylward EH, Whitlock KB, Solomon AC, Queller S, Langbehn DR, Johnson SA, Paulsen JS; Predict-Hd Investigators Of The Huntington Study Group.

Clin Neuropsychol. 2011 Jul;25(5):757-77. doi: 10.1080/13854046.2011.577811.

10.

Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.

Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, Solano RM, Gómez A, Perucho J, Cuervo AM, García de Yébenes J, Mena MA.

Neurobiol Dis. 2010 Sep;39(3):423-38. doi: 10.1016/j.nbd.2010.05.014. Epub 2010 May 28.

PMID:
20546895
11.

The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice.

Perucho J, Casarejos MJ, Rubio I, Rodriguez-Navarro JA, Gómez A, Ampuero I, Rodal I, Solano RM, Carro E, García de Yébenes J, Mena MA.

Exp Neurol. 2010 Jan;221(1):54-67. doi: 10.1016/j.expneurol.2009.09.029. Epub 2009 Oct 6.

PMID:
19815012
12.

Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Mov Disord. 2009 Sep 15;24(12):1763-72. doi: 10.1002/mds.22601.

13.

Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.

Casarejos MJ, Solano RM, Rodriguez-Navarro JA, Gómez A, Perucho J, Castaño JG, García de Yébenes J, Mena MA.

J Neurochem. 2009 Sep;110(5):1523-37. doi: 10.1111/j.1471-4159.2009.06248.x. Epub 2009 Jun 22.

14.

Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.

Mena MA, García de Yébenes J.

Neuroscientist. 2008 Dec;14(6):544-60. doi: 10.1177/1073858408322839. Review.

PMID:
19029058
15.

Weight loss in Huntington disease increases with higher CAG repeat number.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA.

Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e.

PMID:
18981372
16.

Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson's disease.

García-Ruiz PJ, Javier Jiménez-Jiménez F, García de Yébenes J.

Parkinsonism Relat Disord. 1998 Dec;4(4):211-4.

PMID:
18591113
17.

Risk factors for dementia of Alzheimer type and aging-associated cognitive decline in a Spanish population based sample, and in brains with pathology confirmed Alzheimer's disease.

Ampuero I, Ros R, Royuela A, Abraira V, del Ser T, García-Ribas G, García de Yébenes J.

J Alzheimers Dis. 2008 Jun;14(2):179-91.

PMID:
18560129
18.

Glial dysfunction in parkin null mice: effects of aging.

Solano RM, Casarejos MJ, Menéndez-Cuervo J, Rodriguez-Navarro JA, García de Yébenes J, Mena MA.

J Neurosci. 2008 Jan 16;28(3):598-611. doi: 10.1523/JNEUROSCI.4609-07.2008.

19.

Parkin polymorphisms in progressive supranuclear palsy.

Ros R, Ampuero I, García de Yébenes J.

J Neurol Sci. 2008 May 15;268(1-2):176-8. Epub 2007 Nov 26.

PMID:
18022644
20.

[Cerebral amyloid angiopathy and dementias].

García de Yébenes J, Rubio I.

Rev Clin Esp. 2006 Dec;206(11):573-5. Spanish.

PMID:
17178078

Supplemental Content

Loading ...
Support Center